O.10 Chemotherapy choices and doses in frail and elderly patients with advanced colorectal cancer: an MRC randomised clinical trial (FOCUS2)
Michel Seymour(University of Leeds), R.E. Langley, Lindsay C Thompson(MRC Clinical Trials Unit at UCL), Harpreet Wasan(Hammersmith Hospital), Meade, A.E. Brewster, T.S. Maughan, Brandon May(Cheltenham General Hospital), S.F. Shepherd(Cheltenham General Hospital), M.S. O'Mahoney(Cheltenham General Hospital)
Cited by 0
Related Papers
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
|New England Journal of Medicine|2010|4.5k
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
|Journal of Clinical Oncology|2000|3.8k
Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial
|The Lancet|2009|1.5k
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
|New England Journal of Medicine|2019|1.5k